Propanc Health (PPCH) 0.0145 $PPCH Propanc Heal
Post# of 273242
Posted On: 09/19/2016 3:09:34 PM
Propanc Health (PPCH) 0.0145 $PPCH
Propanc Health Group Corporation Presentation Now Available for On-Demand Viewing
PR Newswire - Wed Sep 14, 7:30AM CDT
Company invites individual and institutional investors as well as advisors to log-on to VirtualInvestorConferences.com to view presentation
OTC Company Executives to Present Online to Investors on September 8
PR Newswire - Wed Sep 07, 8:36AM CDT
VirtualInvestorsConferences.com hosts CEOs: live questions answered during online roadshow and in virtual trade booths
CUM.TO: 0.46 (unch)
Propanc Files Application for Orphan Medicinal Product Designation in the EU for Pancreatic Cancer
Marketwire Canada - Wed Sep 07, 7:02AM CDT
MELBOURNE, AUSTRALIA--(Marketwired - September 07, 2016) - Propanc Health Group Corporation (OTCQB: PPCH) ("Propanc" or "the Company"
, an emerging healthcare company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, today announced it has submitted an application for Orphan Medicinal Product Designation (OMPD) to the European Medicines Agency (EMA) for PRP, a solution for intravenous administration of pancreatic proenzymes trypsinogen and chymotrypsinogen. The proposed orphan drug indication for PRP is for the treatment of pancreatic cancer, responsible for 338,000 cancer diagnoses and 331,000 deaths worldwide in 2012, and a major unmet medical issue.
Propanc Health Group Corporation to Webcast, Live, at VirtualInvestorConferences.com September 8
CNW Group - Thu Sep 01, 10:00AM CDT
Company invites individual and institutional investors as well as advisors to attend interactive real-time virtual VirtualInvestorConferences.com
Propanc Retains KCSA Strategic Communications as Investor Relations and Public Relations Counsel
Marketwire Canada - Thu Aug 25, 7:47AM CDT
MELBOURNE, AUSTRALIA--(Marketwired - August 25, 2016) - Propanc Health Group Corporation (OTCQB: PPCH) ("Propanc" or "the Company", an emerging healthcare company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, today announced that it has retained KCSA Strategic Communications, a leading New York-based communications firm, to lead the Company's investor relations and public relations programs.
Propanc Enters Into Contract Manufacturing Agreement With AmatsiQBiologicals
Marketwire Canada - Tue Aug 23, 8:25AM CDT
Development and Production of PRP for Human Use in First-In-Man Studies
Small Biotech Firm, Huge Price Target
ACCESSWIRE - Wed Aug 17, 12:11PM CDT
LAS VEGAS, NV / ACCESSWIRE / August 17, 2016 / Timely research allows brokers and institutions to consider taking positions in development stage companies. One of the more notable research firms in the small cap sector is SeeThruEquity. SeeThruEquity is an approved equity research contributor on Thomson First Call, Capital IQ, FactSet, and Zack's.
Propanc to Present at Rodman & Renshaw 18th Annual Global Investment Conference
Marketwire Canada - Wed Aug 03, 10:26AM CDT
Latest Scientific Research and Preclinical Data for the Company's Lead Product, PRP, as a New Approach to Eradicate Cancer Stem Cells by James Nathanielsz, CEO and Executive Chairman
Propanc Engages Two Advisory Firms to Identify Strategic Partnering Opportunities
PR Newswire - Tue May 31, 7:30AM CDT
Propanc Health Group Corporation (OTCQB: PPCH) ("Propanc" or "the Company", an emerging healthcare company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, today announced that the Company has engaged the services of Maxim Group LLC and Partner International Inc. to initiate potential strategic partnering discussions for the Company's lead product, PRP.
Propanc Completes Successful Roadshow in New York City
PR Newswire - Wed May 11, 7:30AM CDT
Propanc Health Group Corporation (OTCQB: PPCH) ("Propanc" or "the Company", an emerging healthcare company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, today announced that the Company's CEO, Mr. James Nathanielsz, enjoyed a productive week conducting meetings with leading financial institutions and retail brokers in the greater New York area.
FISI: 26.98 (+0.06)
Emerging Growth Apps Company - Making Children Safer and Smarter
ACCESSWIRE - Thu May 05, 7:02AM CDT
MIAMI, FL / ACCESSWIRE / May 5, 2016 / Apps Company, WorldFlix, Inc. (OTC Pink: WRFX) - is an apps company which founded Swantry and Drobbits with children in mind.
Propanc Health Group Corporation Presentation Now Available for On-Demand Viewing
PR Newswire - Wed Sep 14, 7:30AM CDT
Company invites individual and institutional investors as well as advisors to log-on to VirtualInvestorConferences.com to view presentation
OTC Company Executives to Present Online to Investors on September 8
PR Newswire - Wed Sep 07, 8:36AM CDT
VirtualInvestorsConferences.com hosts CEOs: live questions answered during online roadshow and in virtual trade booths
CUM.TO: 0.46 (unch)
Propanc Files Application for Orphan Medicinal Product Designation in the EU for Pancreatic Cancer
Marketwire Canada - Wed Sep 07, 7:02AM CDT
MELBOURNE, AUSTRALIA--(Marketwired - September 07, 2016) - Propanc Health Group Corporation (OTCQB: PPCH) ("Propanc" or "the Company"
, an emerging healthcare company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, today announced it has submitted an application for Orphan Medicinal Product Designation (OMPD) to the European Medicines Agency (EMA) for PRP, a solution for intravenous administration of pancreatic proenzymes trypsinogen and chymotrypsinogen. The proposed orphan drug indication for PRP is for the treatment of pancreatic cancer, responsible for 338,000 cancer diagnoses and 331,000 deaths worldwide in 2012, and a major unmet medical issue. Propanc Health Group Corporation to Webcast, Live, at VirtualInvestorConferences.com September 8
CNW Group - Thu Sep 01, 10:00AM CDT
Company invites individual and institutional investors as well as advisors to attend interactive real-time virtual VirtualInvestorConferences.com
Propanc Retains KCSA Strategic Communications as Investor Relations and Public Relations Counsel
Marketwire Canada - Thu Aug 25, 7:47AM CDT
MELBOURNE, AUSTRALIA--(Marketwired - August 25, 2016) - Propanc Health Group Corporation (OTCQB: PPCH) ("Propanc" or "the Company"
, an emerging healthcare company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, today announced that it has retained KCSA Strategic Communications, a leading New York-based communications firm, to lead the Company's investor relations and public relations programs. Propanc Enters Into Contract Manufacturing Agreement With AmatsiQBiologicals
Marketwire Canada - Tue Aug 23, 8:25AM CDT
Development and Production of PRP for Human Use in First-In-Man Studies
Small Biotech Firm, Huge Price Target
ACCESSWIRE - Wed Aug 17, 12:11PM CDT
LAS VEGAS, NV / ACCESSWIRE / August 17, 2016 / Timely research allows brokers and institutions to consider taking positions in development stage companies. One of the more notable research firms in the small cap sector is SeeThruEquity. SeeThruEquity is an approved equity research contributor on Thomson First Call, Capital IQ, FactSet, and Zack's.
Propanc to Present at Rodman & Renshaw 18th Annual Global Investment Conference
Marketwire Canada - Wed Aug 03, 10:26AM CDT
Latest Scientific Research and Preclinical Data for the Company's Lead Product, PRP, as a New Approach to Eradicate Cancer Stem Cells by James Nathanielsz, CEO and Executive Chairman
Propanc Engages Two Advisory Firms to Identify Strategic Partnering Opportunities
PR Newswire - Tue May 31, 7:30AM CDT
Propanc Health Group Corporation (OTCQB: PPCH) ("Propanc" or "the Company"
, an emerging healthcare company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, today announced that the Company has engaged the services of Maxim Group LLC and Partner International Inc. to initiate potential strategic partnering discussions for the Company's lead product, PRP. Propanc Completes Successful Roadshow in New York City
PR Newswire - Wed May 11, 7:30AM CDT
Propanc Health Group Corporation (OTCQB: PPCH) ("Propanc" or "the Company"
, an emerging healthcare company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, today announced that the Company's CEO, Mr. James Nathanielsz, enjoyed a productive week conducting meetings with leading financial institutions and retail brokers in the greater New York area. FISI: 26.98 (+0.06)
Emerging Growth Apps Company - Making Children Safer and Smarter
ACCESSWIRE - Thu May 05, 7:02AM CDT
MIAMI, FL / ACCESSWIRE / May 5, 2016 / Apps Company, WorldFlix, Inc. (OTC Pink: WRFX) - is an apps company which founded Swantry and Drobbits with children in mind.
(0)
(0)Scroll down for more posts ▼